On September 24, 2009
Who’s Afraid of Big, Bad Cardiovascular? Apparently Not Biotech…
Cardiovascular disease brings to mind huge, expensive clinical trials and huge, expensive primary care sales forces…but not necessarily huge, expensive drug prices. With the basics of cholesterol management met, some big pharmas are turning away from the field, but enterprising biotechs are stepping in.
0 Comments